Atai Life Sciences Valued At More Than $3 Billion After IPO
German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
Entries by Jill Ettinger
27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On
These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.
The War On Drugs May Finally Be Over: Decriminalization Legislation Comes to Congress
Representatives Cori Bush and Bonnie Watson Coleman have introduced legislation to end the federal war on drugs once and for all.
Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation
Atai Life Sciences is the latest psychedelic company to announce plans to IPO. The Peter Thiel-backed biotech startup is valued at more than $2 billion.
AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million
Nue Life Health is a new therapy platform relying on AI and music as well as psychedelics for customized healing.
Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange
Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.
Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE
Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.
Research to Look at Psychedelics for Autism Treatment
New research from Nova Mentis will explore the potential benefits of psychedelics in treating autism spectrum disorders.
Texas Senate Approves Psychedelic Research Legislation Aimed at Military Veterans
Texas has moved closer to legal psychedelic research for PTSD military veterans after the state senate approved the legislation.
Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries
Cannabis-focused Enveric Biosciences will acquire Canadian psychedelic drug discovery platform MagicMed Industries.
